Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3. Issue 2 (December 2015) - Powderly, John; Cote, Gregory; Flaherty, Keith; Szmulewitz, Russell; Ribas, Antoni; Weber, Jeffrey; Loo, Deryk; Baughman, Jan; Chen, Francine; Moore, Paul; Bonvini, Ezio; Vasselli, James; et al.